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Lower extremity bypass vs endovascular therapy
for young patients with symptomatic peripheral
arterial disease
Mauri J. A. Lepäntalo, MD,a Rabih Houbballah, MD,b Maxime Raux, MDb and
Glenn LaMuraglia, MD,b Helsinki, Finland; and Boston, Mass
The uncertainty continues over the best approach to patients with symptomatic peripheral arterial disease. Medical
therapy and risk factor modification is part of any treatment regimen; with this there is little disagreement. However,
with the introduction of lesser invasive percutaneous technologies, the discussion regarding surgical and endovascular
therapies has become more and more complicated. Unfortunately, there is a relative shortage of robust outcomes data to
support many of our specific treatment recommendations. Younger patients are an especially troublesome patient cohort.
They have consistently shown poorer outcomes after any intervention compared with older patients and may represent a
subset of more aggressive atherosclerotic disease. Our debaters will discuss their preferred approaches to these difficult
patients in the context of the currently available supporting literature. ( J Vasc Surg 2012;56:545-55.)
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PPART I: LOWER EXTREMITY BYPASS IS THE
PREFERRED TREATMENT FOR PATIENTS
AGED <65 YEARS OLD WITH SYMPTOMATIC
INFRAINGUINAL ARTERIAL DISEASE
Mauri J. A. Lepäntalo, MD, Helsinki, Finland
Age is an issue. Younger patients have longer life ex-
pectancy and thus need more durable treatment solutions.
Of 1725 consecutive infrainguinal revascularizations for
symptomatic peripheral arterial disease (PAD) in Helsinki
University Central Hospital, as many as 482 patients (28%)
belonged to this group of patients aged65 years. Most of
revascularized legs had critical limb ischemia (CLI): among
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ld was 60%, whereas it was 48% in older patients.
Intermittent claudication. Intermittent claudication
aused by infrainguinal arterial disease can mostly be
reated conservatively. Yet, when functional capacity is
hreatened, claudication may need to be treated by revas-
ularization. This should not be done too hastily, because
ny kind of revascularization may be the onset of a vicious
ycle of repeated interventions that may accelerate the
therwise benign course of PAD.1 Furthermore, scientific
vidence is lacking concerning the efficacy of endovascular
herapy on claudication.2
CLI. Patients with CLI represent 5% of those with
ymptomatic PAD. In younger age groups, CLI is encoun-
ered typically in diabetic patients, and a number of isch-
mic and neuroischemic lesions in diabetic patients do not
eet the strict definition of CLI. The risk for amputation at
metatarsal or higher level is eightfold higher in a diabetic
atient compared with a nondiabetic patient.3 In addition,
ype I diabetic patients reach an 86-fold increased risk for
ny nontraumatic amputation at age 65 years.4 Despite
evascularization, ischemic lesions have a slow tendency for
ealing in diabetics.5 In this patient group, the 5-year
urvival of patients65 years old was 60%, while it was 48%
n older patients in Helsinki.
This is why a durable revascularization should be used
o allow wound healing in this young group of patients.
n-line arterial flow to the pedal level offers the best results
n patients with CLI, as shown by the 10-year data from
omposelli et al6 with results from 1032 limb salvage
ypasses to the dorsalis pedis artery in 865 patients. In this
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August 2012546 Lepäntalo et alstudy, the patency of saphenous vein grafts was better than
any other conduit, with a secondary patency rate of 67.6%
at 5 years.6 No comparable data are available for endovas-
cular treatment.
Results mean everything. Patency is a direct measure
of revascularization success when reopening or bypassing
occlusions.7 Patency is the key criterion for judging the
primary effectiveness of a revascularization but is less often
described than leg salvage and amputation-free survival, or
even wound healing, quality of life, and sustained ambula-
tion. Patient-related outcomes are, of course, important
but strongly affected by other measures than treatment
modality itself.
Leg survival or leg salvage. Leg salvage or foot pres-
ervation, a favored and easy to retrieve end point of CLI
studies, is problematic because a number of factors other
than revascularization affect the outcome. Leg salvage is an
indirect measure of the success of revascularization. The
key question is what the leg outcome would be if untreated
or treated conservatively. Indeed, in studies reporting out-
come of patients with CLI unsuitable for revascularization
(CLI verified by ankle pressure50mmHg or toe pressure
30 mm Hg), 1-year leg survival rates of 54%,8 58% for
controls with spinal cord stimulation,9 and 66% in patients
with an ankle-brachial index 0.5 were reported.10 In this
last study,Marston, et al10 reported a wound healing rate of
52% at 1 year. The results of any revascularization should be
compared with these data. Four large recent series of bypass
surgery for CLI reported leg salvage rates of 88% to 92% at
1 year.6,11–13 The 5-year leg salvage rate of 78% in these
four series underlines the durability of bypass surgery.6
Endovascular treatment had 82% to 86% leg salvage rates at
1 year.14,15 Lu et al16 summed up the limited experience
available in using distal venous arterialization as the last resort
procedure to avoid major amputation, and even that method
was associated with 71% leg salvage at 1 year (Fig 1).
Mind the gap! We should be careful when considering
Fig 1. Leg survival at 1 year after treatment of critical
cord stimulation,9 venous arterialization,16 percutaneouthe so-called patency/leg-salvage gap, which seems wider in flndovascular than in surgical series; that is, occlusion of the
evascularized segment leads to amputation less often after an
ndovascular procedure than after surgical bypass, as summa-
ized by Romiti et al.14 This gap can be explained in different
ays. One hypothesis is that leg salvage exceeding the patency
f the revascularization procedure is attributable to the early
atency, which provides adequate perfusion until ischemic
esions are healed. Thereafter, the leg stays viable if infection is
leared and proper foot care is sustained, especially with dia-
etic lesions. This concept may, of course, be partly true, but
more obvious explanation is that legs treated by endovascu-
ar methods have milder lesions, as illustrated for instance by
he impressive results of Faglia et al.17 Leg salvage is actually
he improvement achieved by therapeutic measures above
atural leg survival (Fig 2).
Apples and oranges. Percutaneous transluminal an-
ioplasty (PTA) was recommended for stenosis and bypass
or occlusions in the first TransAtlantic Inter-Society Con-
ensus (TASC) document.18 In the second TASC docu-
ent,19 PTAwas still recommended for stenosis and bypass
or long occlusions, but there was no consensus on therapy
or short and moderate occlusions (Table I). Endovascular
herapy for infrapopliteal arterial disease is gaining accep-
ance as a first-line method to improve ulcer healing and
imb salvage, despite lack of evidence. In a recent meta-
nalysis on infrapopliteal surgery and infrapopliteal endo-
ascular interventions11,14 with 29 and 30 studies included,
espectively, 88% of patients were diabetic and 88% had
issue loss among the 2320 in the bypass group, whereas
1% were diabetic and 76% had tissue loss among the 2653
n the endovascular group. No distal pressure measurement
as available in this study. Primary and secondary midterm
atency rates were better after bypass, but there was no
ifference in limb salvage. The results of this meta-analysis
re biased by the heterogeneity of indications, risk factors,
umber of treated arterial segments, lesion type (occlusion
s stenosis), lesion length, lesion characteristics, and out-
ischemia (CLI) using conservative treatment,8-10 spinal
sluminal angioplasty (PTA),14,15 and bypass.11-13limbow. In this setting, TASC II classification of femoropop-
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Volume 56, Number 2 Lepäntalo et al 547liteal lesions is not very helpful.20 Furthermore, many stud-
ies are flawed for a number of other reasons.21,22 The
bypass groups most likely include patients with more severe
disease, and only a rather small share of infrainguinal lesions
are equally well-treatable with either method (Table I).
Data from randomized controlled trials. When en-
dovascular and surgical revascularization are both techni-
cally feasible, no significant difference was observed in
symptomatic relief in the few randomized controlled trials
(RCT) that included both suprainguinal and infrainguinal
revascularizations for mixed indications.2 There are two
RCTs, includingmostly claudicants with superficial femoral
artery (SFA) occlusions, which suggest that surgical bypass
gives better results than the endovascular approach.23,24
Another RCT25,26 that included a large variety of lesions
and mixed indications observed similar outcome after both
approaches (Table II).
The British Angioplasty vs Surgery in Ischaemic Legs
(BASIL) trial is the only large RCT that compared endo-
vascular revascularization and bypass surgery.27 Only pa-
tients with CLI or at least severe ischemia and potential
Fig 2. Leg salvage at 1 year after treatment of critical
arterialization,16 percutaneous transluminal angioplasty
shows leg salvage attributable to patent revascularization
Table I. Summary of recommendations of the TransAtlan
Level of disease
S
Usually PTA (type A) PTA preferred (typ
Femoropopliteal SFA stenosis 10 cm or
occlusion 5 cm
SFA stenosis or
occlusion 15
popliteal stenos
Crural Nonea Nonea
Outcomes Excellentb Excellentb
PTA, Percutaneous transluminal angioplasty; SFA, superficial femoral artery
aCrural interventions have severe outcomes if they go wrong; therefore ther
bExcellent results can be expected from an endovascular approach in all segcandidates for infrainguinal angioplasty or bypass were ancluded, and 42% of patients were diabetic. Both ap-
roaches yielded similar results in amputation-free survival
p to 2 years. Surgery was associated with higher postop-
rative morbidity, more hospital days, and higher costs, and
ngioplasty was associated with higher need for further
evascularization procedures.27 However, the long-term
esults suggested that surgical repair was more durable,29
ut no patency data were available. The results of the
ASIL trial emphasize the role of bypass over PTA in fit
atients with a saphenous vein available,29 and this was the
ase in 75% of the patients in BASIL trial.
The generalizability of the BASIL trial was audited
rom a sample of 456 patients with infrainguinal lesions,
36 of whom underwent a revascularization procedure but
nly 29% were suitable for randomization (ie, treatment by
ither method). This finding illustrates the narrow overlap
f the indications for endovascular and surgical revascular-
zation.
The same holds particularly true with the Scandinavian
hrupass vs Bypass Study, in which SFA occlusions were
andomized between polytetrafluoroethylene endografting
ischemia (CLI) with spinal cord stimulation,9 venous
),14,15 and bypass.11-13 The shaded area of the column
ter-Society Consensus II Working Group22
nt/recommendation
Surgery preferred (type C) Usually surgery (typeD)
SFA stenosis or occlusion
15 cm; recurrent
disease
Complete SFA or popliteal
occlusions
Stenoses 4 cm or
occlusions 2 cm
Diffuse disease or occlusions
2 cm
PTA/stent only has modest
results and is indicated
when surgery is
contraindicated for
technical or patient
reasons.
Endovascular approach is not
advised unless symptoms
are limb threatening and
surgery is not possible.
type A or B recommendation.
.limb
(PTAtic In
egme
e B)
cm;
is
.
e is nond polytetrafluoroethylene bypass grafting.24 Only 4% of
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August 2012548 Lepäntalo et althe SFA occlusions met the tight inclusion criteria chosen
to exclude short occlusions and all lesions with unfavorable
landing zones for an endograft. This illustrates the difficult
balance between internal and external validity. But when
comparable patients are analyzed, bypass seems to give a
better result.23,24,29 These data are far less cited than those
suggesting noninferiority of endovascular methods (Table
II).
The findings of the BASIL trial suggest that whether
to perform bypass or PTA first for CLI due to infraingui-
nal disease depends on life expectancy.29 Long-term
results favoring bypass were also observed in a large
cohort study of 858 CLI patients with a propensity score
analysis.30
Complications and costs. Admittedly, bypass sur-
gery is followed by a number of perioperative and late
complications. LaMuraglia et al31 recently reported a
high incidence of complications related to bypass sur-
gery, according to an American private sector database,
with 2.7% mortality and 18.7% major complications,
including 7.4% graft thrombosis. In this extended series,
complications were associated with age 80 years and
poor preoperative functional status.32 Thus, it is difficult
to use these data directly to assess the risk of bypass for
patients aged 65 years.
The complications of PTA are said to be rare and minor
and not to preclude a bypass at a later date. Yet, crural
interventions may have severe outcomes that cannot be
corrected.22 Furthermore, technical failure rates of 20% are
associated with attempts to open infrapopliteal occlu-
sions,33 and procedural complication rates of 7% to 17%
have been reported.14,15,32 Furthermore, an early death
rate of 2.7% in a mixed series indicated that a crural PTA-
first strategy is not without risk.34 Finally, the main predic-
tor of outcome is not the approach used but the patient’s
risk profile.
According to the BASIL trial,29 surgery was associ-
Table II. Patency data in randomized controlled studies com
First author,
year
Centers, study
period Concealment No.
De
ischemia
Van der Zaag,23
2004
13 (1995-1998) () 57
Adam,27 2005
Bradbury,28
2010
27 (1999-2004)  452 II
Kedora,25
2007
1 private
(2004-2005)
– 86 (100
legs)
I
McQuade,26
2009
Lepäntalo,24
2009
8 (2003-2007)  44 II (89
(
() Concealment not clearly stated; ARR, absolute risk reduction; CI, c
transluminal angioplasty; PTFE, polytetrafluoroethylene; SFA, superficial fem
II classification; vsm, vena saphena magna.ated with higher number of days in the hospital and the oeed for advanced postoperative care. The mean cost of
npatient treatment was one-third higher for a bypass-
rst than for a PTA-first strategy, but this was true only
uring the first year. After 2 years, the cost of repeated
ew interventions abolished this difference.29 In addi-
ion, what the costs of unnecessary interventions are is
nclear.
Loss of ambulation is also an important cause of
ncrease in costs. Goodney et al12 reported a 81% sus-
ained ambulation rate at 1 year in patients treated by
ypass for CLI.
The approaches to maximize early detection and
ptimize therapy for PAD have been emphasized in the
iterature with the hope to lessen the number of patients
ith CLI.35 This is absolutely true for risk factors and
est medical treatment, but there are no data to show
hat indications for revascularizations should be ex-
ended. Regional data from Southern Finland have
hown that endovascular activity for CLI has been dou-
led during the past 5 years but without any positive
ffect on major amputation rates. An interesting al-
hough biased analysis could be made using the present
ata to assess the effectiveness of the current practice
Figs 1 and 2). To save one leg for 1 year, three to four
egs should be treated by bypass operations and six to
even legs by endovascular interventions. Indeed, scien-
ific evidence is lacking to assess the true efficacy of
ndovascular therapy on critical ischemia.2
ONCLUSIONS
The aim is always to revascularize the leg properly in
LI, with a resulting well-perfused foot to allow ulcer
ealing. A durable solution can be achieved by bypass using
ood-quality saphenous vein and by ascertaining good
utflow. Bypass surgery and endovascular interventions are
omplementary techniques for revascularization. If endo-
ascular and bypass procedures were possible with equal
ng infrainguinal surgical and endovascular revascularization
f
taine) Lesions treated Interventions
SFA occlusions 5-15 cm
(91%) and stenoses
(9%)
PTA vs bypass (vein 79%)
Infrainguinal lesions
chosen for intervention
on the basis of principle
of equipoise
PTA first (80% SFA) vs
bypass first (vsm 75%,
infrapopliteal outflow 33%)
strategies
SFA stenoses and
occlusions (TASC A-D)
PTFE endograft vs bypass
(PTFE or polyester)
I-IV SFA occlusions 5-25 cm PTFE endograft vs bypass
(PTFE)
nce interval; HR, hazard ratio; PP, primary patency; PTA, percutaneous
rtery; SP, secondary patency; TASC, TransAtlantic Inter-Society Consensuspari
gree o
(Fon
II
I-IV
I-IV
%); II
11%)
onfideutcomes, then endovascular treatments would be pre-
11
1
1
1
1
1
1
1
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Volume 56, Number 2 Lepäntalo et al 549ferred. However the main issue, especially in younger pa-
tients, is the durability of the revascularization: better to
trust a bypass with a good vein to an artery with good
outflow. Despite early PAD in patients 65 years old, the
longevity is not shortened to an extent to allow the second
best treatment of choice to be selected.
Endovascular techniques and equipment are devel-
oping rapidly, but scientific evidence of these new meth-
ods is scarce. Level I evidence concerning subintimal
angioplasty, drug-eluting balloons, cryoplasty, and the
other latest endovascular innovations do not exist. When
available, scientific data include mainly short case-series,
and because new techniques are introduced all the time,
the target is moving too rapidly to collect proper scien-
tific data.
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PART II: ENDOVASCULAR THERAPY IS THE
PREFERRED TREATMENT FOR PATIENTS
AGED <65 YEARS OLD WITH SYMPTOMATIC
INFRAINGUINAL ARTERIAL DISEASE
Rabih Houbballah, MD, Maxime Raux, MD, and
Glenn LaMuraglia, MD, Boston, Mass
During the last 30 years, the understanding and medi-
cal management of peripheral arterial disease (PAD) hasvolved considerably. Although traditional surgical recon-
truction had been the mainstay treatment for failure of
edical or local wound therapy, the introduction and
evelopment of endovascular procedures has significantly
xpanded the therapeutic options for treating this patient
opulation. Between 1995 and 2000, catheter-based inter-
entions for infrainguinal disease had increased by nearly
000%.1 In addition, for the first time, there has been a
oncurrent decrease in the major amputation rates in “at-
isk patients,” although one has to be cautious about
inking this outcome improvement to a specific treatment
odality or care improvement.2
It is sometimes difficult to assess and compare new
odalities of care, such as endovascular procedures, with
raditional bypass surgery. This is especially true when
onsidering lower extremity peripheral occlusive disease,
here the type of symptomatic presentation, the corre-
ponding anatomic obstructions, the plaque composition,
nd systemic patient metabolic abnormalities provide a
ide spectrum of disease and a very heterogeneous popu-
ation that makes correlating clinical end points between
reatment modalities very challenging. This difficulty is
urther amplified with recent, rapid improvements of med-
cal therapy for atherosclerotic occlusive disease that have
ad a varied geographic penetration into this population of
atients.
Despite these limitations, some comparisons can be
ade. When analyzing periprocedural outcomes of infrain-
uinal revascularization during the last decade, endovascu-
ar treatment has a significantly lower procedural morbidity
nd mortality, and hospital length of stay, compared with
pen bypass surgery.3 With ease of patient tolerance of
hese procedures and increased familiarity of vascular spe-
ialists with its capabilities, endovascular therapy is increas-
ngly considered as the initial treatment of choice for symp-
omatic patients with PAD, whether the lesions are simple
r complex, focal or diffuse, single or multiple, calcified, or
oncalcified.4,5 Multiple clinical trials have confirmed that
n endovascular-first approach reduces morbidity, mortal-
ty, and costs while preserving surgical options for subse-
uent revascularizations.6–8
Opponents of the use of percutaneous transluminal
ngioplasty (PTA) as the initial treatment emphasize its
nferior long-term primary patency compared with vein
raft bypass surgery. To maintain a comparable midterm
nd long-term assisted patency and limb salvage with PTA,
atients frequently require secondary procedures more of-
en than after bypass surgery. For this reason, these propo-
ents believe that in young patients with a reasonable
ong-term life expectancy, bypass surgery should be the
rst-line treatment. To argue an endovascular first-line
trategy, even in patients aged  65 years, the following
rguments will be proposed:
. Patients with PAD have a significantly reduced life ex-
pectancy, making use of an endovascular approach a
timely consideration.
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Volume 56, Number 2 Lepäntalo et al 5512. Periprocedural morbidity andmortality are considerably
lower with PTA.
3. Secondary interventions after primary endovascular fail-
ure are safe, effective, and provide assisted-patency and
limb salvation comparable to undertaking first-line by-
pass surgery.
4. Bypass failure, compared with PTA failure, can be an
ominous event for patients with PAD, resulting in poor
outcome for limb preservation.
5. Costs between PTA and bypass are comparable.
Patients with PAD have a significantly reduced life
expectancy, making use of an endovascular approach a
timely consideration. Excluding patients with critical
limb ischemia (CLI), who have even worse longevity, pa-
tients with symptomatic PAD have 5-, 10- and 15-year
all-cause mortality rates of 30%, 50%, and 70%, respec-
tively.9 In fact, the mortality rate of patients with claudica-
tion is 2.5 times higher than age-matched controls.9 Pa-
tients with chronic CLI have a 20%mortality in the first year
after presentation, and the recent long-term results of the
British Angioplasty vs Surgery in Ischemic Legs (BASIL)
trial showed a 56%mortality rate at 4 years,10 while another
recent cohort study in this patient population identified a
12% annual death rate.5
Coronary artery disease is by far the most common
cause of death among patients with PAD (40%-60%), with
cerebral artery disease accounting for 10% to 20% of
deaths.9 There are multiple predictive factors of death in
PAD patients that can further stratify the individual pa-
tient’s risk, including age, presence of tissue loss, serum
creatinine, extent of coronary artery disease and cerebro-
vascular disease, severity of the PAD itself, bodymass index,
smoking status, pulmonary disease, and congestive heart
failure.7,11,12
Therefore, patients with symptomatic PAD have a sig-
nificantly shortened longevity compared with the general
population. Thus, when considering a treatment for symp-
tomatic infrainguinal disease, minimizing periprocedural
morbidity and rehabilitation time take on a higher impor-
tance, whereas extended durability of the reconstructions,
although always a high priority, need to be considered
relative to the patient’s life expectancy.
Periprocedural morbidity and mortality are consid-
erably lower with PTA. There has been good evidence
that the more extensive the vascular procedure the higher
the periprocedural morbidity and mortality.13,14 In a large,
prospective, contemporary series of 2404 patients (mean
age, 67 years) undergoing infrainguinal bypass surgery, the
30-day mortality was 2.7%, with a composite mortality/
major morbidity rate of 19.5%.13 Major complications oc-
curred in 18.7%, which encompassed 9.4% wound infec-
tions and 7.4% graft thromboses. A subanalysis of these
data for only claudication patients (52%), revealed a lower
mortality of 2% and composite major morbidity/mortality
of 14.5%. Results were comparable in the prospective,
randomized Edifoligide for the Prevention of Infrainguinal
Vein Graft Failure (PREVENT) III trial (mean age, 68 mears) of vein graft bypass in patients with CLI that identi-
ed a 30-day mortality of 2.7% with major complications of
7.8%.15
With judicious hydration and limiting iodinated con-
rast administration, periprocedural morbidity after PTA is
nusual and mostly due to groin hematoma, bleeding, and
evelopment of a pseudoaneurysm.5 Complication rates of
% to 5% have been reported in claudication patients16,17
nd 2% to 5% in CLI patients.7 A recent large study of PTA
n CLI patients (mean age, 70 years) reported a rate of 4%
f groin or retroperitoneal hematoma requiring transfu-
ion.5
Mean hospital stay after an infrainguinal PTA is 1 
.02 days, with an immediate return to active life, especially
n intermittent claudication patients, whereas length of stay
fter surgery is 4.52  0.31 days.18 When short-term
utcomes of infrainguinal vein bypass are examined, hospi-
al readmissions 6 months have been reported in 49% of
atients, 65% of which were related to problems resulting
rom the index operation.6 Because there is lower compli-
ation rate for PTA, the 30-day hospital readmission rate
as been reported to be 6%.19
PAD, and especially CLI, causes a natural reduction of
hysical function. The ultimate goal in these patients is a
unctional status and quality of life. A study evaluating
iabetic patients at 6 months after undergoing infraingui-
al bypass for limb salvage reported that less than half of the
atients felt being “back to normal,” and 74% of patients
equired devices to assist with walking.20 Interestingly, the
unctional status at follow-up was independent of patient
ge in this primarily diabetic cohort.
Another study focusing on functional outcomes after
ypass for CLI identified a 19% loss of ambulation and a 5%
oss of independent living.21 A recent meta-analysis exam-
ned preoperative and postoperative ambulatory status and
ndependent living in patients undergoing revasculariza-
ion for CLI. Of the 10 studies that reviewed postoperative
ypass outcomes at 6 to 12months, there was a 12% decline
n ambulatory status and a 15% loss of semi-independent
iving.22 The meta-analysis found only one study that eval-
ated ambulatory status 12months after PTA in a cohort of
22 patients, and there was a 6% loss of ambulatory sta-
us.22 The BASIL trial also addressed this issue in the
hort-term and long-term follow-up data, with no signifi-
ant improvement in quality of life found between the PTA
nd bypass groups.23
In summary, infrainguinal treatment for symptomatic
AD with PTA offers a lower rate of perioperative morbid-
ty and mortality than bypass for patients with claudication
nd CLI, resulting in a faster return to normal daily activity.
Secondary interventions after primary endovascular
ailure are safe, effective and provide assisted patency
nd limb salvage comparable to undertaking first-line
ypass surgery. Results of the BASIL randomized study
onfirmed that endovascular and vein graft bypass treatment
f CLI have a similar amputation-free survival and assisted
linical success rates at 2 years.6 Comparison between two
eta-analyses of infrageniculate reconstruction for CLI
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August 2012552 Lepäntalo et alfound popliteal-to-distal vein bypass grafts24 and infrapop-
liteal angioplasty25 provided similar outcomes. Both stud-
ies used similar methods and targeted the same patient
population. At 1 and 6 months, and at 1, 2, and 3 years,
primary patency were higher with bypass reconstruction.
However, overall limb salvage was comparable in both
meta-analyses (82%).24,25
Using PTA to treat the femoral-popliteal segment also
provides very respectable outcomes, with primary and as-
sisted patency of 65% and 93%, respectively, at 3 years.17
Infrapopliteal PTAwith 40months average follow-up iden-
tified a primary patency of 62%, an assisted patency of 90%,
and an overall limb preservation rate of 86%.7 More re-
cently, an evaluation at 5 years of 409 CLI patients treated
with PTA as a first-line therapy demonstrated a low primary
patency of 31%, an assisted patency that improved to 75%,
and an excellent limb salvage rate of 74%.5
The BASIL study is the only randomized study to try to
answer the question of superiority of a bypass surgery-first
strategy vs a PTA-first strategy in treatment of CLI pa-
tients.6 The 5-year results do indicate that in the analysis of
only the subgroup of patients who have survived 2 years
after randomization (subset of survivors, not all patients),
there was a significantly higher overall survival in the by-
pass-first group but not a significant higher amputation-
free survival, even suggesting they may be different patient
cohorts.26 There was also a higher early failure rate of
PTA-first patients compared with surgery-first patients, and
that many of the PTA-first patients ultimately required
bypass surgery. Another conclusion was that surgical pa-
tients who had undergone prior PTA had worse outcomes
than those who only had surgery.10 However, this did not
address the specific question of whether a prior PTA later
excluded, by loss of anatomic runoff, a subsequent surgical
option, but rather that patients who had surgery after failed
PTA did not fare as well as those who only had a primary
surgery. Indeed, because this is a group of a failed interven-
tion, they may have been more appropriately compared
with the group who had surgery after a failed surgical
procedure.
Although the BASIL trial is Level I evidence data, there
are several problems with it that would indicate some
caution in the data interpretation. The investigational site
audits, including the suitability of randomization, consent,
and crossover to the opposite arm of the study, resulted in
approximately one in 10 presenting patients actually enroll-
ing in the study arm that they were originally randomized
to, thus somewhat preselecting the cohort of patients en-
tered into the study. In addition, the PTA arm of the study
was undertaken primarily by radiologists and the surgery
arm by the surgeons, which might have introduced differ-
ences in the approach and the treatment of these complex
patients with multilevel disease.10
A large, prospective, registry-based study of infrapopli-
teal procedures in CLI highlighted that bypass and surgery
achieved similar 5-year rates of leg salvage (75.3% vs
76.0%), survival (47.5% vs 43.3%), and amputation-free
survival (37.7% vs 37.3%).27 To reduce confounding fac- aors, a propensity score was used to analyze the data, which
ielded equivalent results of both PTA-first and bypass-first
reatment arms.
PTA of the superficial femoral artery has better primary,
ssisted primary, and secondary patency than prosthetic
ypass in the above-knee position.28 Femorodistal bypasses
ith a prosthetic graft have a very low secondary patency
25% at 5 years) and are known to have loss of outflow
uring graft failure.29 Therefore, in patients with no avail-
ble venous conduit or who are at a high risk for bypass,
TA can be considered the preferred initial therapy for
ransAtlantic Inter-Society Consensus (TASC) B and C
esions.30
In summary, infrainguinal vein bypass have the highest
rimary patency rates long-term. However, through close
ollow-up and secondary interventions, similar limb salva-
ion rates can be achieved with PTA treatment. Midterm
nd long-term patency are better with PTA compared with
rosthetic bypass.
Bypass failure, compared with PTA failure, can be
n ominous event for patients with PAD, resulting in
oor outcome for limb preservation. When performed
y an experienced interventionist who understands the
imits of the technique and the subsequent surgical options
or revascularization, an attempted or failed PTA for in-
rainguinal arterial disease can be very often safely treated
y a new PTA or a surgical bypass. Multiple studies have
emonstrated that first-line therapy with PTA/stent does
ot preclude reintervention with PTA or a secondary sur-
ical revascularization.17,31,32 All studies showed that sec-
ndary bypass feasibilities, patency, and limb salvation rates
ere similar to the primary bypass patency and feasibili-
ies.33,34 The contradiction of these observations in the
ASIL study10 was addressed in the previous section. An-
ther study raised the question of a prior PTA resulting in
lower success rate of subsequent bypass.35 There were
everal limitations in this study. The data were obtained
rom a database where the anatomic site and the number of
TA prior to bypass were unknown. In addition, the group
ith a prior PTA was mostly female and required the use of
rm vein conduit, two factors associated with inferior long-
erm patency.
Consequences of a failed infrainguinal bypass can be
ore deleterious.36 Early graft failure (1 month of sur-
ery) has been reported in approximately 5% to 10% of
atients37,38 and has been correlated with increased limb
oss.37 In addition, the long-term secondary patency of a
hrombosed vein graft that has undergone thrombectomy
r thrombolysis is 36% at 1 year.39 Reoperative bypass
urgery for a failed graft also has inferior results. Results of
hose secondary bypass surgeries are also poor (14% early
raft failure with vein graft and 30% with prosthetic grafts,
0% primary patency at 5 years with venous bypass), which
s mainly due to severe scarring in the operative field or lack
f ipsilateral saphenous vein that necessitates use of alter-
ative poor vein conduits or prosthetic grafts.40,41
In summary, the percutaneous procedure should be
lways undertaken with consideration of backup surgical
11
1
1
1
1
1
1
1
1
2
2
2
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 2 Lepäntalo et al 553options should the initial PTA be unsuccessful or fail.
Thrombosis of a bypass is a poor prognostic factor, because
secondary patency is poor and secondary bypasses have
diminished long-term patency.
Costs between PTA and bypass are comparable. In
the BASIL trial, the periprocedural morbidity of the PTA-
first strategy was significantly lower than the bypass-first
strategy. As a consequence, the resource utilization and
hospital length of stay were significantly higher in the
surgery group. This was responsible for a mean hospital
cost one-third higher in the bypass group during the first
year.6,42 Owing to a higher rate of reintervention over the
duration of the study in the PTA-first cohort, the cost
between the two groups equalized by the end of the
study.23 Cost analysis also depends on practice patterns, use
of stents, and differences in the patient’s clinical presenta-
tion. In addition, the equipment expenditure between
2001 and 2007 has seen the average cost for PTA increase
60% for claudication and limb-threatening ischemia,
reaching $14,084 and $23,196, respectively.18 From, re-
cent data comparing PTA and surgical treatment in appro-
priately selected patients, the amortized cost per day of
patency is comparable in claudication or chronic limb isch-
emia patients.8
CONCLUSIONS
Although treatment of risk factors for PAD has made
significant advances in the last several decades, failure of
medical therapy resulting in symptomatic infrainguinal oc-
clusive disease relies on PTA or bypass to improve perfu-
sion. Because patients with PAD have a shorter life expec-
tancy than the general population, the most effective
method of revascularization to return patients back to their
functional state would be ideal. This would entail symp-
tomatic relief, with minimal morbidity and lesion healing, if
present, as the critical end points. In addition to minimal
periprocedural morbidity, PTA has a better limb salvage
rate and assisted patency than prosthetic bypass and results
that approach the gold standard of venous bypass. Never-
theless, because bypass surgery may become a future treat-
ment modality, care should be taken not to undertake PTA
options that may obviate those possible future treatments.
Even as the present algorithms of medical, interventional,
and surgical care for claudication and limb-threatening
ischemia remain highly controversial, they have resulted in
a 25% decrease the major lower extremity amputation rate
within the last 15 years.2
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210, iii-iv.EDITORS’ COMMENTARYThomas L. Forbes, MD, and Jean-Baptiste Ricco, M
Our debaters have argued their preferred approaches for
younger patients with symptomatic peripheral arterial disease
(PAD) and have included such issues as procedure-related mor-
bidity, patency and durability, reinterventions, and life expec-
tancy. A similar discussion could occur regarding younger pa-
tients with abdominal aortic aneurysms and the comparative
value of an endovascular or open repair. However, this analogy
is not entirely appropriate. Whereas durability of the repair and
need for reintervention is especially relevant in these young
aneurysm patients with their longer life expectancies, young
PAD patients represent a group with more aggressive systemic
atherosclerotic disease. At best, these younger patients can
expect an absolute life expectancy similar to their older symp-
tomatic PAD counterparts.1
The early presentation of symptomatic PAD is a marker of
coinciding premature atherosclerotic disease in the coronary
and carotid circulations. Medical therapy and risk factor modi-
fication are especially vital in these patients, regardless of the
operative or interventional approach used for their PAD. Spe-
cific risk factors, including lipoprotein(a) level 30 mg/dL,
have been identified as risk factors for premature PAD, espe-
cially in men.2 Despite adequate medical therapy and diabetes
management, these patients are at increased risk for major
cardiovascular events. Recent evidence would suggest that
young women with PAD are especially susceptible to cardiovas-hD, London, Ontario, Canada; and Poitiers, France
Along with a more aggressive form of systemic atherosclerotic
isease, young PAD patients appear to be predisposed to multiple
rocedures or interventions. A review of younger men with symp-
omatic PAD found 40% required multiple interventions because
f progression of their disease or bypass graft failure.1 Predictors of
reatment failure have been investigated recently. In a cohort of
hinese patients, 38% of young PAD patients had thrombophilia
hat proved to be an independent predictor of graft thrombosis and
ajor amputation at 30 days and of decreased patency and limb
alvage after 1 year.4
Young patients with symptomatic PAD represent an espe-
ially challenging group for vascular surgeons. As with older
atients, they represent a population with aggressive systemic
therosclerosis and a somewhat limited life expectancy. Aggres-
ive medical therapy and risk factor modification are mandatory,
nd the choice of bypass or endovascular therapy for their PAD
eeds to reflect this limited life expectancy. In PAD patients of
ll ages in the Bypass vs Angioplasty in Severe Ischaemia of the
eg (BASIL) trial,5 bypass with adequate great saphenous vein
as superior to angioplasty in those with a life expectancy 2
ears.
Regardless, the optimal therapy should limit periprocedural
orbidity and mortality, should be durable, require few—if any—
einterventions, and be successful in resolving symptoms and avoid-
ng major amputation. These are complex decisions and should be
ndividualized to the patient’s symptoms, anatomy, and comorbidi-
